{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:10:11Z","timestamp":1769839811978,"version":"3.49.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T00:00:00Z","timestamp":1710201600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s13555-024-01127-x","type":"journal-article","created":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T06:07:44Z","timestamp":1710223664000},"page":"1049-1056","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Atypical Fibroxanthoma Treated with a Topical Combination of Imiquimod, Tazarotene, and 5-Fluorouracil"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2335-8780","authenticated-orcid":false,"given":"William J.","family":"Nahm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos V.","family":"Badiavas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Kirsner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carter J.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita A.","family":"Arthur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,3,12]]},"reference":[{"key":"1127_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11864-017-0489-6","volume":"18","author":"T Soleymani","year":"2017","unstructured":"Soleymani T, Tyler HS. Conception and management of a poorly understood spectrum of dermatologic neoplasms: atypical fibroxanthoma, pleomorphic dermal sarcoma, and undifferentiated pleomorphic sarcoma. Curr Treat Options Oncol. 2017;18:1\u201311.","journal-title":"Curr Treat Options Oncol"},{"issue":"2","key":"1127_CR2","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/j.1524-4725.2010.01843.x","volume":"37","author":"I Iorizzo","year":"2011","unstructured":"Iorizzo I, Luciano J, Brown MD. Atypical fibroxanthoma: a review of the literature. Dermatol Surg. 2011;37(2):146\u201357.","journal-title":"Dermatol Surg"},{"key":"1127_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.975342","volume":"12","author":"D Helbig","year":"2022","unstructured":"Helbig D, Klein S. Immune checkpoint inhibitors for unresectable or metastatic pleomorphic dermal sarcomas. Front Oncol. 2022;12:975342.","journal-title":"Front Oncol"},{"issue":"3","key":"1127_CR4","doi-asserted-by":"publisher","first-page":"260","DOI":"10.36849\/JDD.5427","volume":"20","author":"WJ Nahm","year":"2021","unstructured":"Nahm WJ, Shen J, Zito PM, et al. A non-surgical and cost-effective treatment approach employing topical imiquimod, 5-fluorouracil, and tretinoin for primary non-melanoma skin cancers. J Drugs Dermatol. 2021;20(3):260\u20137.","journal-title":"J Drugs Dermatol"},{"issue":"3","key":"1127_CR5","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/modpathol.2017.146","volume":"31","author":"KG Griewank","year":"2018","unstructured":"Griewank KG, Wiesner T, Murali R, et al. Atypical fibroxanthoma and pleomorphic dermal sarcoma harbor frequent NOTCH1\/2 and FAT1 mutations and similar DNA copy number alteration profiles. Mod Pathol. 2018;31(3):418\u201328.","journal-title":"Mod Pathol"},{"issue":"2","key":"1127_CR6","doi-asserted-by":"publisher","first-page":"158","DOI":"10.5114\/jcb.2017.65454","volume":"9","author":"S Doggett","year":"2017","unstructured":"Doggett S, Brazil J, Limova M, et al. Electronic brachytherapy management of atypical fibroxanthoma: report of 8 lesions. J Contemp Brachytherapy. 2017;9(2):158\u201360.","journal-title":"J Contemp Brachytherapy"},{"issue":"6","key":"1127_CR7","doi-asserted-by":"publisher","first-page":"e429","DOI":"10.1016\/j.jaad.2020.07.022","volume":"83","author":"D Rosenfeld","year":"2020","unstructured":"Rosenfeld D, Alam M, Van Tine B, Council ML. Atypical fibroxanthoma: a malignant tumor of the skin and soft tissue. J Am Acad Dermatol. 2020;83(6):e429\u201330.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1127_CR8","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1111\/jdv.15493","volume":"33","author":"O Persa","year":"2019","unstructured":"Persa O, Loquai C, Wobser M, et al. Extended surgical safety margins and ulceration are associated with an improved prognosis in pleomorphic dermal sarcomas. J Eur Acad Dermatol Venereol. 2019;33(8):1577\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"1127_CR9","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2019.1665977","volume":"8","author":"S Klein","year":"2019","unstructured":"Klein S, Persa O-D, Mauch C, et al. First report on two cases of pleomorphic dermal sarcoma successfully treated with immune checkpoint inhibitors. Oncoimmunology. 2019;8(12): e1665977.","journal-title":"Oncoimmunology"},{"issue":"4","key":"1127_CR10","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1001\/archderm.140.4.404","volume":"140","author":"UR Hengge","year":"2004","unstructured":"Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol. 2004;140(4):404\u20136.","journal-title":"Arch Dermatol"},{"issue":"4","key":"1127_CR11","doi-asserted-by":"publisher","first-page":"354","DOI":"10.4103\/0253-7613.161249","volume":"47","author":"AK Bubna","year":"2015","unstructured":"Bubna AK. Imiquimod - its role in the treatment of cutaneous malignancies. Indian J Pharmacol. 2015;47(4):354\u20139.","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"1127_CR12","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1016\/j.jaad.2020.12.049","volume":"84","author":"L Maxfield","year":"2021","unstructured":"Maxfield L, Shah M, Schwartz C, Tanner LS, Appel J. Intralesional 5-fluorouracil for the treatment of squamous cell carcinomas. J Am Acad Dermatol. 2021;84(6):1696\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1127_CR13","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jaad.2003.07.003","volume":"52","author":"F Bardazzi","year":"2005","unstructured":"Bardazzi F, Bianchi F, Parente G, Guareschi E, Landi C. A pilot study on the use of topical tazarotene to treat squamous cell carcinoma in situ. J Am Acad Dermatol. 2005;52(6):1102\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1127_CR14","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.3390\/curroncol28040213","volume":"28","author":"L Bennardo","year":"2021","unstructured":"Bennardo L, Bennardo F, Giudice A, et al. Local chemotherapy as an adjuvant treatment in unresectable squamous cell carcinoma: what do we know so far? Curr Oncol. 2021;28(4):2317\u201325.","journal-title":"Curr Oncol"},{"issue":"24","key":"1127_CR15","doi-asserted-by":"publisher","first-page":"2228","DOI":"10.2174\/1568026619666191009165418","volume":"19","author":"DC McGowan","year":"2019","unstructured":"McGowan DC. Latest advances in small molecule TLR 7\/8 agonist drug research. Curr Top Med Chem. 2019;19(24):2228\u201338.","journal-title":"Curr Top Med Chem"},{"key":"1127_CR16","doi-asserted-by":"publisher","DOI":"10.5070\/D34VW339W4","author":"D Navi","year":"2004","unstructured":"Navi D, Huntley A. Imiquimod 5 percent cream and the treatment of cutaneous malignancy. Dermatol Online J. 2004. https:\/\/doi.org\/10.5070\/D34VW339W4.","journal-title":"Dermatol Online J"},{"issue":"1","key":"1127_CR17","doi-asserted-by":"publisher","first-page":"S6","DOI":"10.1067\/mjd.2000.107808","volume":"43","author":"DN Sauder","year":"2000","unstructured":"Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000;43(1):S6\u201311.","journal-title":"J Am Acad Dermatol"},{"key":"1127_CR18","doi-asserted-by":"publisher","first-page":"xv","DOI":"10.1111\/j.0022-202X.2004.22537.x","volume":"122","author":"M Leverkus","year":"2004","unstructured":"Leverkus M. Imiquimod: unexpected killer. J Investig Dermatol. 2004;122:xv\u2013xvi.","journal-title":"J Investig Dermatol"},{"issue":"8","key":"1127_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3390\/molecules13081551","volume":"13","author":"N Zhang","year":"2008","unstructured":"Zhang N, Yin Y, Xu S-J, Chen W-S. 5-Fluorouracil: mechanisms of resistance and reversal strategies. Molecules. 2008;13(8):1551\u201369.","journal-title":"Molecules"},{"issue":"2","key":"1127_CR20","first-page":"73","volume":"473","author":"PV Danenberg","year":"1977","unstructured":"Danenberg PV. Thymidylate synthetase-a target enzyme in cancer chemotherapy. Biochim Biophys Acta. 1977;473(2):73\u201392.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"1127_CR21","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1016\/j.bmcl.2008.03.016","volume":"18","author":"A Jarmu\u0142a","year":"2008","unstructured":"Jarmu\u0142a A, Dowiercia\u0142 A, Rode W. A molecular modeling study of the interaction of 2\u2032-fluoro-substituted analogues of dUMP\/FdUMP with thymidylate synthase. Bioorg Med Chem Lett. 2008;18(8):2701\u20138.","journal-title":"Bioorg Med Chem Lett"},{"issue":"5","key":"1127_CR22","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1021\/bi101536k","volume":"50","author":"JB Parker","year":"2011","unstructured":"Parker JB, Stivers JT. Dynamics of uracil and 5-fluorouracil in DNA. Biochemistry. 2011;50(5):612\u20137.","journal-title":"Biochemistry"},{"key":"1127_CR23","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1007\/s00018-008-8557-5","volume":"66","author":"MD Wyatt","year":"2009","unstructured":"Wyatt MD, Dr W. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009;66:788\u201399.","journal-title":"Cell Mol Life Sci"},{"key":"1127_CR24","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1365-4632.2009.04045.x","volume":"48","author":"D Askew","year":"2009","unstructured":"Askew D, Mickan S, Soyer P, Wilkinson D. Effectiveness of 5-fluorouracil treatment for actinic keratosis - a systematic review of randomized controlled trials. Int J Dermatol. 2009;48:453\u201363.","journal-title":"Int J Dermatol"},{"issue":"11","key":"1127_CR25","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1016\/j.clinthera.2004.11.012","volume":"26","author":"AR Shalita","year":"2004","unstructured":"Shalita AR, Berson DS, Thiboutot DM, et al. Effects of tazarotene 0.1% cream in the treatment of facial acnevulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther. 2004;26(11):1865\u201373.","journal-title":"Clin Ther"},{"issue":"4","key":"1127_CR26","first-page":"438","volume":"12","author":"SR Feldman","year":"2013","unstructured":"Feldman SR, Werner CP. The efficacy and tolerability of tazarotene foam, 0.1%, in the treatment of acne vulgaris in 2 multicenter, randomized, vehicle-controlled, double-blind studies. J Drugs Dermatol. 2013;12(4):438\u201346.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"1127_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1001\/archderm.137.12.1597","volume":"137","author":"S Kang","year":"2001","unstructured":"Kang S, Leyden JJ, Lowe NJ, et al. Tazarotene cream for the treatment of facial photodamage: a multicenter, investigator-masked, randomized, vehicle-controlled, parallel comparison of 0.01%, 0.025%, 0.05%, and 0.1% tazarotene creams with 0.05% tretinoin emollient cream applied once daily for 24\u00a0weeks. Arch dermatol. 2001;137(12):1597\u2013604.","journal-title":"Arch dermatol"},{"issue":"9","key":"1127_CR28","first-page":"16","volume":"12","author":"S Sidgiddi","year":"2019","unstructured":"Sidgiddi S, Allenby K, Okumu F, Gautam A. Bioavailability, pharmacokinetics, and transepidermal water loss of short contact tazarotene lotion 0.1% versus tazarotene (Tazorac\u00ae) cream 0.1%. J Clin Aesth Dermatol. 2019;12(9):16.","journal-title":"J Clin Aesth Dermatol"},{"issue":"s49","key":"1127_CR29","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2133.1996.tb15662.x","volume":"135","author":"R Chandraratna","year":"1996","unstructured":"Chandraratna R. Tazarotene\u2014first of a new generation of receptor-selective retinoids. Br J Dermatol. 1996;135(s49):18\u201325.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1127_CR30","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1067\/mjd.2003.618","volume":"49","author":"H Gollnick","year":"2003","unstructured":"Gollnick H, Cunliffe W, Berson D, et al. Management of acne: a report from a global alliance to improve outcomes in acne. J Am Acad Dermatol. 2003;49(1):S1\u201337.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"1127_CR31","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1111\/j.0022-202X.2004.23498.x","volume":"123","author":"M Papoutsaki","year":"2004","unstructured":"Papoutsaki M, Lanza M, Marinari B, et al. The p73 gene is an anti-tumoral target of the RAR\u03b2\/\u03b3-selective retinoid tazarotene. J Investig Dermatol. 2004;123(6):1162\u20138.","journal-title":"J Investig Dermatol"},{"issue":"20","key":"1127_CR32","doi-asserted-by":"publisher","first-page":"12622","DOI":"10.3390\/ijms232012622","volume":"23","author":"B Ramchatesingh","year":"2022","unstructured":"Ramchatesingh B, Mart\u00ednez Villarreal A, Arcuri D, et al. The use of retinoids for the prevention and treatment of skin cancers: an updated review. Int J Mol Sci. 2022;23(20):12622.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"1127_CR33","first-page":"3249","volume":"6","author":"M Duvic","year":"2000","unstructured":"Duvic M, Helekar B, Schulz C, et al. Expression of a retinoid-inducible tumor suppressor, tazarotene-inducible gene-3, is decreased in psoriasis and skin cancer. Clin Cancer Res. 2000;6(8):3249\u201359.","journal-title":"Clin Cancer Res"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01127-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01127-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T02:32:40Z","timestamp":1714185160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01127-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,12]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1127"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01127-x","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,12]]},"assertion":[{"value":"5 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"William J. Nahm, Evangelos V. Badiavas, Robert S. Kirsner, Carter J. Boyd, Anita A. Arthur, Sean Bae, and John Shen have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As this is a case report, ethics committee approval and consent for participation were not required. The authors obtained written consent from patients for their photographs and medical information to be published in print and online with the understanding that this information may be publicly available. Patient consent forms were not provided to the journal but are retained by the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}